此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults

This study is a open and multiple dose escalation phase I clinical study, aiming to evaluate the pharmacokinetic characteristics and safety of Benaglutide Injection in overweight/obese adults after multiple subcutaneous injections.

This study will enroll 16 overweight/obese adults, both male and female. The trial was divided into two batches, including 4 subjects who completed all dosing, safety assessment and telephone follow-up, and the remaining 12 subjects who were enrolled for the trial. All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.

Subjects will be screened at D-14-D-2, and eligible subjects D-2 will be admitted to the phase I clinical trial ward at D-2. D-1 Blank blood samples were collected at different time points before and after breakfast for PK test baseline correction. D1 began by subcutaneously injecting different doses of benaglutide injection 5 minutes before the daily three meals, collecting biological samples at different time points after the first administration of D6, D7, D11, D12 and D16 to evaluate the pharmacokinetic characteristics of Benaglutide. Subjects will be discharged after all samples are collected and safety assessed at D17. Telephone follow-up was performed on the 7th day after discharge (D24±2) to further observe safety.

研究概览

地位

完全的

研究类型

介入性

注册 (实际的)

16

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Shandong
      • Qingdao、Shandong、中国、266003
        • The Affiliated Hospital of Qingdao University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female aged between 18 and 70 years old (including the critical value).
  • BMI meets the following requirements (a or b):

    1. BMI>28 kg/m2;
    2. BMI>24 kg/m2 with at least one of the following symptoms:

Vigorous appetite, hunger before meals unbearable, each meal into more food. Combined with hyperglycemia, hypertension, dyslipidemia, fatty liver in one or several.

Combined with weight-bearing joint pain. Obesity causes dyspnea or obstructive sleep apnea syndrome.

  • The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG.
  • The subjects have no family planning within 3 months and could select contraceptive method.
  • Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.

Exclusion Criteria:

  • Patients with type 1 diabetes or type 2 diabetes with a clear diagnosis;
  • Fasting intravenous blood glucose ≥7 mmol/L or 75g during screening. Oral glucose tolerance test (OGTT) two hours after glucose load;
  • Fasting venous blood glucose <2.8 mmol/L at screening, and/or those with a history of hypoglycemia;
  • Those who complained of a weight change of >5% within 3 months before screening;
  • Have used weight loss drugs or hypoglycemic drugs that may affect body weight within 4 weeks before screening;
  • Drugs used within 4 weeks before screening that may cause significant weight gain: including systemic glucocorticoid therapy (lasting more than 1 week); tricyclic antidepressants; antipsychotic or antidepressant drugs; may interfere with blood sugar regulation Functional medicine; all proprietary Chinese medicines and Chinese herbal medicines;
  • Those who have a clear history of malignant tumors,
  • People with Cushing's syndrome, hypothyroidism, polycystic ovary disease or other genetic endocrine diseases or medical history;
  • Those who have a history of bariatric surgery;
  • Have a history of multiple endocrine tumors or a family history; have a history of medullary thyroid carcinoma or other tumors, a family history;
  • History of acute and chronic pancreatitis;
  • Moderate to severe gastrointestinal diseases with additional gastrointestinal motility disorders or obstructive enteropathy;
  • Have a clear history of mental illness

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Benaglutide Injection
All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
血浆浓度与时间曲线下面积 (AUC)0-t
大体时间:80天
血浆浓度与时间曲线下面积 (AUC)0-t 的评估
80天
Peak Plasma Concentration (Cmax)
大体时间:80 days
Evaluation of Peak Plasma Concentration (Cmax)
80 days
Area under the plasma concentration versus time curve (AUC)0-∞
大体时间:80 days
Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞
80 days
elimination half-life time(T1/2)
大体时间:80 days
Evaluation of elimination half-life time(T1/2)
80 days
The total clearance(CL)
大体时间:80 days
Evaluation of the total clearance(CL)
80 days

次要结果测量

结果测量
措施说明
大体时间
Incidence of Treatment Adverse Events
大体时间:80 days
Collection of adverse events
80 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年7月7日

初级完成 (实际的)

2020年12月1日

研究完成 (实际的)

2021年5月20日

研究注册日期

首次提交

2022年1月28日

首先提交符合 QC 标准的

2022年1月28日

首次发布 (实际的)

2022年2月7日

研究记录更新

最后更新发布 (实际的)

2022年2月7日

上次提交的符合 QC 标准的更新

2022年1月28日

最后验证

2022年1月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • RH-RCT-IS-002

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Benaglutide Injection的临床试验

3
订阅